Cure8 trial brief
The study explores breath VOCs as a possible noninvasive biomarker for IBD activity, which could offer easier, more acceptable monitoring than colonoscopy or stool tests.
Adults with Crohn's disease or ulcerative colitis; clinicians and researchers focused on noninvasive IBD monitoring or biomarker development.
This is a completed observational registry (planned n=292) that enrolled adults undergoing endoscopy and obtained breath samples (disposable mouth filter), serum, and stool. The study's primary outcome was correlation of breath VOCs with objective IBD activity measures over one year, including fecal calprotectin.
Participants with recent antibiotics, certain surgical histories (colectomy, ostomy), pregnancy, or other major comorbidities were excluded.
This registry is observational and focused on correlating VOCs with objective inflammation markers (fecal calprotectin, endoscopy). Results are not presented in the record; breath-VOC diagnostics remain investigational until validated in outcome studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
Self‑management programs delivered by nurses may help people with IBD improve daily functioning, confidence in managing their condition, and quality of life even when inflammation markers don’t change. That matters...
